Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure

Area of Science:

• Oncology
• Rheumatology
• Nephrology

Background:

• Systemic sclerosis (scleroderma) is a complex autoimmune disease causing skin thickening and internal organ damage.
• Docetaxel, a chemotherapy drug, is known to cause cutaneous side effects, including rare scleroderma-like skin changes.
• Previous reports linked docetaxel to skin manifestations of scleroderma but not internal organ involvement.

Observation:

• A patient developed systemic sclerosis with pulmonary arterial hypertension and microangiopathic kidney disease after docetaxel chemotherapy.
• The observed scleroderma-like skin changes were extensive, mimicking diffuse cutaneous systemic sclerosis.
• Internal organ involvement, specifically pulmonary and renal, was a significant feature of the patient's condition.

Findings:

• This case represents the first documented instance of docetaxel-induced systemic sclerosis with documented internal organ involvement.
• The findings suggest a potential causal link between docetaxel and severe, multi-systemic scleroderma.
• The patient's pulmonary arterial hypertension and kidney disease were attributed to the docetaxel treatment.

Implications:

• This case highlights the importance of monitoring for systemic sclerosis and its organ complications in patients receiving docetaxel.
• Oncologists and rheumatologists should be aware of this rare but severe potential side effect of docetaxel.
• Further research is warranted to understand the mechanisms underlying docetaxel-induced systemic sclerosis and to develop preventative or therapeutic strategies.